Money for nothing? Risks in biopharmaceutical companies from the perspective of public financiers




Laura Heinonen, Birgitta Sandberg

PublisherSpringer

2008

 Journal of Commercial Biotechnology

14

287

298

12

https://link.springer.com/article/10.1057/jcb.2008.25




Last updated on 26/11/2024 03:55:18 PM